ArticleResearch and practice in thrombosis and haemostasis2026
Temporal validation of the electronic health record cancer-associated thrombosis model in patients with low bleeding risk.
Article in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Background: The electronic health record cancer-associated thrombosis (EHR-CAT) model was derived to predict cancer-associated venous thromboembolism (VTE). Prior validations often relied on cancer registry data with reporting delays. Objectives: We aimed to perform an external temporal validation of the EHR-CAT model among patients at low risk of bleeding using contemporary Veterans Affairs electronic health record data. Methods: We conducted a retrospective cohort study in patients with active cancer who received systemic therapy within the national Veterans Affairs (VA) health care system from 2017 to 2024. The key inclusion criteria included: (1) having readily extractable data for EHR-CAT calculation without cancer registry data, (2) index date at first or subsequent lines of therapy, (3) exclusion of adjuvant endocrine monotherapy with low risk for VTE, and (4) application of anticoagulant clinical trial exclusion criteria to minimize bleeding risk. Patients from previously published studies were excluded. Systemic therapies were defined using the VA Corporate Data Warehouse, and one line was randomly selected. VTE outcomes were determined using validated VTE-Bidirectional Encoder Representations from Transformers natural language processing from clinical notes. Time-dependent C-statistic and calibration slope were assessed. Results: Among 65,341 patients with cancer receiving systemic therapy (42,865 first-line and 22,476 second-line or higher), median age was 71.9 years, and 95% were male. Most common cancers included prostate (16.1%), lung (14.8%), lymphoma (11.5%), and bladder (11.1%). The VTE incidence at 6 months was 5.4%. VTE was observed in 1.9%, 4.0%, 4.7%, 6.5%, 9.6%, and 12.3% of patients with EHR-CAT scores 0-, 1, 2, 3, 4, and 5+, respectively (C-statistic 0.67). Calibration slope was 0.876. Conclusion: The EHR-CAT model, when applied across different lines of therapy, demonstrated similar performance as in previous studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.